FI119359B - Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina - Google Patents

Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina Download PDF

Info

Publication number
FI119359B
FI119359B FI973118A FI973118A FI119359B FI 119359 B FI119359 B FI 119359B FI 973118 A FI973118 A FI 973118A FI 973118 A FI973118 A FI 973118A FI 119359 B FI119359 B FI 119359B
Authority
FI
Finland
Prior art keywords
ifn
cells
complexes
mab
indications
Prior art date
Application number
FI973118A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI973118A7 (fi
FI973118A0 (fi
Inventor
Jeffrey L Browning
Christopher D Benjamin
Werner Meier
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of FI973118A0 publication Critical patent/FI973118A0/fi
Publication of FI973118A7 publication Critical patent/FI973118A7/fi
Application granted granted Critical
Publication of FI119359B publication Critical patent/FI119359B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI973118A 1995-01-26 1997-07-25 Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina FI119359B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
US37896895 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
US9601386 1996-01-26

Publications (3)

Publication Number Publication Date
FI973118A0 FI973118A0 (fi) 1997-07-25
FI973118A7 FI973118A7 (fi) 1997-09-25
FI119359B true FI119359B (fi) 2008-10-31

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973118A FI119359B (fi) 1995-01-26 1997-07-25 Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina

Country Status (24)

Country Link
EP (2) EP0809510B1 (da)
JP (2) JPH10513161A (da)
KR (2) KR100475492B1 (da)
CN (3) CN1589902A (da)
AT (1) ATE268604T1 (da)
AU (1) AU725351B2 (da)
BG (1) BG62599B1 (da)
BR (1) BR9606808A (da)
CA (1) CA2211443A1 (da)
CZ (1) CZ298711B6 (da)
DE (1) DE69632681T2 (da)
DK (1) DK0809510T3 (da)
EA (1) EA000096B1 (da)
EE (1) EE04453B1 (da)
ES (1) ES2220972T3 (da)
FI (1) FI119359B (da)
HU (1) HUP9801746A3 (da)
NO (1) NO322744B1 (da)
NZ (1) NZ303405A (da)
PL (1) PL185364B1 (da)
PT (1) PT809510E (da)
RO (1) RO118634B1 (da)
SK (1) SK286497B6 (da)
WO (1) WO1996022788A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CZ20011272A3 (cs) 1998-10-09 2001-09-12 Biogen, Inc. Použití činidla, které blokuje vazbu lymfotoxinu-beta na jeho receptor, pro výrobu protivirového léku
PL366307A1 (en) * 2000-10-13 2005-01-24 Biogen, Inc. Humanized anti-lt-beta-r antibodies
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
MX2011003352A (es) * 2008-09-30 2011-05-02 Genentech Inc Marcadores biologicos predictivos de la respuesta de la artritis reumatoide a antagonistas de linfotoxina.
RU2014124984A (ru) * 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
JPH06501456A (ja) * 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
CA2150249A1 (en) * 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof

Also Published As

Publication number Publication date
DE69632681D1 (de) 2004-07-15
WO1996022788A1 (en) 1996-08-01
KR20040102364A (ko) 2004-12-04
KR19980701816A (ko) 1998-06-25
KR100470739B1 (ko) 2005-09-02
JP2007169296A (ja) 2007-07-05
SK286497B6 (sk) 2008-11-06
CZ236197A3 (cs) 1998-02-18
HUP9801746A2 (hu) 1998-11-30
EP1407781A1 (en) 2004-04-14
EA199700144A1 (ru) 1997-12-30
CN1900116A (zh) 2007-01-24
HUP9801746A3 (en) 2000-11-28
PT809510E (pt) 2004-09-30
HK1006356A1 (en) 1999-02-26
FI973118A7 (fi) 1997-09-25
NO973385L (no) 1997-09-25
EE9700255A (et) 1998-04-15
ES2220972T3 (es) 2004-12-16
CZ298711B6 (cs) 2008-01-02
CN1589902A (zh) 2005-03-09
NZ303405A (en) 2000-02-28
PL185364B1 (pl) 2003-04-30
NO322744B1 (no) 2006-12-04
KR100475492B1 (ko) 2005-03-14
AU4970496A (en) 1996-08-14
NO973385D0 (no) 1997-07-22
CN1146442C (zh) 2004-04-21
CN1177302A (zh) 1998-03-25
BG62599B1 (bg) 2000-03-31
EA000096B1 (ru) 1998-08-27
EE04453B1 (et) 2005-04-15
BG101855A (en) 1998-04-30
MX9705629A (es) 1997-10-31
ATE268604T1 (de) 2004-06-15
AU725351B2 (en) 2000-10-12
FI973118A0 (fi) 1997-07-25
PL321758A1 (en) 1997-12-22
BR9606808A (pt) 1997-12-30
RO118634B1 (ro) 2003-08-29
EP0809510B1 (en) 2004-06-09
DK0809510T3 (da) 2004-10-04
EP0809510A1 (en) 1997-12-03
JPH10513161A (ja) 1998-12-15
DE69632681T2 (de) 2005-06-09
SK98697A3 (en) 2000-02-14
CA2211443A1 (en) 1996-08-01

Similar Documents

Publication Publication Date Title
FI119359B (fi) Lymfotoksiini-alfa/beta-komplekseja ja anti-lymfotoksiini-beta-reseptor ivasta-aineita kasvaintenvastaisina aineina
US6312691B1 (en) Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
Browning et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.
KR101004174B1 (ko) 세포소멸을 유도하는 시토킨
US6284236B1 (en) Cytokine that induces apoptosis
US20030059427A1 (en) Isolation and characterization of highly active anti-CD40 antibody
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US6015559A (en) Fas antagonists
WO1994020625A1 (en) Method for inducing tumor cell death
MXPA97005629A (en) Linfotoxin-alpha / beta complexes and anti-tetration antibodies of lymphotoxin beta as agents anti-tu
HK1006356B (en) Lymphotoxin-alpha/beta complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
HK1065472A (en) Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
Browning Signaling through the Lymphotoxin 13 Receptor Induces the Death of Some Adenocarcinoma Tumor Lines By Jeffrey L. Browning, Konrad Miatkowski, Irene Sizing, David Griffiths, Mohammad Zafari, Christopher D. Benjamin, Werner Meier, and Fabienne Mackay

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: BIOGEN IDEC MA INC.

Free format text: BIOGEN IDEC MA INC.

FG Patent granted

Ref document number: 119359

Country of ref document: FI